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1. Introduction    
Human pluripotent stem cells (hPSCs, which include both human embryonic and induced 
pluripotent stem cells [hESCs and hiPSCs]) provide a unique model system to study early 
human development, derive functionally mature cell populations, and hold great promise to 
advance medical treatments for currently incurable diseases. Modulating gene function in 
these cells is of critical importance to gain insight into the molecular underpinnings of the 
pluripotent state and the process of differentiation. Furthermore, efficient transgenesis in 
hPSC is essential in generating cells carrying specific disease-associated alleles, thereby 
enabling the study of human diseases at the cellular level.  
In contrast to murine ESCs, hESCs have proven quite recalcitrant to gene modification using 
many of the traditional methods. The reason(s) for this difference between mESCs and 
hESCs are poorly understood, but it has been postulated that hESCs represent a slightly 
different stage with distinct developmental potential than mESCs and that this difference 
accounts for the differences observed in transgenesis and homologous recombination 
(Buecker et al., 2010).  
DNA can be introduced into hPSCs using viral and non-viral methods, yielding both 
transient and stable transduction. Stable integration into the genome can occur at random 
sites, thus potentially disrupting endogenous gene expression or function. In addition, 
transduced cell lines can be selected to carry targeted gene insertions through site-specific 
recombination or homologous recombination. In this chapter, we describe several methods 
to transduce genetic elements into hPSCs and discuss their strengths and weaknesses.  
2. Random transgenesis 
Several methods have been used successfully to randomly integrate DNA into the genome 
of hPSCs and thereby generating marker lines that express reporter genes in a cell- or tissue-
specific manner. The most commonly used methods to transduce DNA into cells, either 
transiently or stably, involve chemical-based transfection reagents, electroporation, or viral 
infection. The advantages and limitations of each transgenic method will be discussed in the 
following section. In general, transgenic approaches to create reporter lines are limited by 
the fact that regulatory elements controlling cell-specific gene expression are often either 
poorly defined or located at great distances from the gene. To faithfully reproduce a gene 
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expression pattern may require DNA fragment lengths that exceed conventional 
recombinant DNA methods. In addition, stably transduced reporter genes may be under 
control of endogenous regulatory elements near the sight of integration. For example, 
genetic integration into certain compact regions of the genome can lead to silencing or lower 
levels of expression due to reduced accessibility of transcription factors. Another caveat of 
using random insertional transgenesis is that in rare instances gene insertion may interrupt 
expression of other genes that influence cell phenotype. As a result of these positional 
effects, screening and analysis of multiple clones for reporter gene expression patterns over 
time and during differentiation must be performed. Unfortunately, generation of single-cell 
clones is often difficult given the low cloning efficiency of hESCs (Amit et al., 2000). 
Recently, this challenge has been partially mitigated by the use of neurotrophins (such as 
NT3 and NT4) (Pyle et al., 2006) or selective inhibitors of Rho-associated kinase ROCK (e.g. 
Y-27632) (Damoiseaux et al., 2009; Watanabe et al., 2007), both of which increase survival of 
dissociated hESCs.  
The methods described in this section have been used to introduce transgenes encoding 
fluorescent proteins or drug resistance markers under the transcriptional control of cell-
specific promoters into hPSCs. Specific sub-populations of cells expressing the reporter gene 
can be enriched and isolated using drug selection or flow cytometry-based cell sorting.  
2.1 Electroporation  
Electroporation involves the use of electric pulses of varying voltage, length, and number to 
transiently increase the permeability of the cell membrane and permit entry of DNA. Several 
groups have reported the use of electroporation for the transfection of hESCs (Eiges et al., 
2001; Lakshmipathy et al., 2004; Mohr et al., 2006; Zwaka and Thomson, 2003). Using a 
plasmid containing a gene encoding green fluorescent protein (GFP) under control of a 
cytomegalovirus immediate-early gene 1 (CMV) promoter/enhancer, Mohr et al. 
investigated the electroporation parameters of pulse, voltage, duration, and number on 
hESC viability and transfection efficiency (Mohr et al., 2006). A single 300V, 0.5 millisecond 
pulse achieved an optimum survival rate of 50% and a transient transfection rate of 10%. 
These values were consistent with other reported transfection efficiencies using 
electroporation (Lakshmipathy et al., 2004). It is important to note that this study focused on 
the transient transfection of plasmid DNA. In contrast, stable transfection efficiencies are 
much lower because of the low rate of DNA integration into the genome. Typically, 
transient transgene expression in hESCs is not retained for longer than 5 passages (Vallier et 
al., 2004). By comparison, the yield of stably transfected clones using electroporation has 
been reported to be on the order of 1 in 10-5 (Adewumi et al., 2007; Zwaka and Thomson, 
2003). Moreover, less than 1% of electroporated hESCs in single-cell suspension survive 
(Zwaka and Thomson, 2003). However, electroporation of hESCs in clumps suspended  
in standard cell culture medium greatly improved cell survival (Zwaka and Thomson,  
2003). 
2.2 Nucleofection  
Nucleofection is a recently developed and commercialized technology (Amaxa® 
Nucleofector® Technology, Lonza) that expands on the principles of electroporation. 
Specifically, nucleofection is a customized procedure in which buffer solutions and electric 
pulses are optimized for specific cell types (Siemen et al., 2005; Siemen et al., 2008). In 
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contrast to electroporation, in which efficiency is dependent on cell cycle because DNA only 
enters the nucleus when the nuclear envelope is fragmented during cell division, 
nucleofection leads to a direct transfer of the DNA into the cell nucleus (Hamm et al., 2002). 
Nucleofection of a GFP reporter construct into hESCs yielded survival rates of >70% and a 
transient transgene expression of 66% in surviving cells. Furthermore, transfected cells 
maintained expression of markers of pluripotency, such as TRA-1-60 and OCT4, and could 
be expanded to stably expressing clones. Additionally, the small amount of cells and DNA 
required for nucleofection has allowed it to be a valuable tool for high-throughput genetic 
manipulation of hESCs (Moore et al., 2010). 
2.3 Chemical-based transfection methods 
As an alternative to electroporation, chemical transfection reagents (lipid and polymer-
based reagents) have been used in attempts to achieve substantial levels of transgene 
expression in hESCs. The commonly used calcium-phosphate (Ca/PO4) mediated 
transfection methods have had limited success in hESCs, due to the cytotoxicity of the 
Ca/PO4 precipitate.  
An early report compared the efficiency of three different lipofection-based reagents, 
Lipofectamine (Invitrogen), Fugene (Boehringer Mannnheim) and ExGen 500 (Fermentas), 
in hESCs by using an expression construct in which GFP was under control of the 
elongation factor I (EF1α) promoter (Eiges et al., 2001). Transient transfection with ExGen 
500 resulted in transgene expression an order of magnitude higher than Lipofectamine or 
Fugene. However, GFP transgene expression occurred in only 10% of the ExGene500 
transfected cells, a transfection efficiency comparable to electroporation. This report conflicts 
with that of others (Siemen et al., 2005), which state that ExGen 500 was less effective than 
other reagents such as Lipofectamine and Fugene. One study compared several chemical 
transfection reagents and confirmed the poor efficiency of ExGen 500 and determined that 
GeneJammer was the most effective method (Anderson et al., 2007). A recent report 
describes the development of a class of polymers, poly(β-amino esters), which have higher 
gene delivery efficiencies because of their ability to condense DNA into nanoparticles, thus 
enhancing cellular uptake (Green et al., 2008). These nanoparticles have gene delivery 
efficiencies 4 times higher than other transfection reagents such as Lipofectamine. It is 
important to note that the reported differences between the efficacies of these reagents could 
be attributed to differences in the culture systems and individual hESC lines tested. 
Therefore, some reagents may be better suited for use in specific hESC lines. 
In order to achieve stable transfection into hESCs using chemical-based transfection 
methods, a gene encoding antibiotic-resistance or fluorescent protein must be present in the 
construct so that stable transfectants can be selected. HESC lines developed employing such 
methods have been utilized to monitor the differentiation status of hESCs. Eiges et al. used 
lipofection to transfect hESCs with GFP under the control of a murine Rex1 promoter, a gene 
that is rapidly downregulated upon differentiation of hESCs (Eiges et al., 2001). The 
transfected hESCs could be sorted to homogeneity using fluorescent-activated cell sorting 
(FACS). The purified cell population showed high levels of GFP expression when in an 
undifferentiated state. As the cells differentiated this expression was significantly reduced. 
Along similar lines, lipofection was used to generate a hESC line with GFP driven by an 
OCT4 promoter. Such OCT4-GFP lines have proven useful in monitoring the exit from the 
undifferentiated state and acquisition of differentiation markers. 
www.intechopen.com
 Methodological Advances in the Culture, Manipulation and  
Utilization of Embryonic Stem Cells for Basic and Practical Applications 
 
280 
Chemical-based transfection methods have also been used to tag and purify specific hESC 
derivatives. For example, chemical transgenic methods were used to enrich cardiomyocytes 
using a reporter system in which the human α-myosin promoter drove expression of 
puromycin–N-acetyltransferase (PAC)(Anderson et al., 2007). Positive selection with 
puromycin of hESCs differentiated towards cardiomyocytes resulted in a cardiomyocytes 
enrichment of 14.5 fold (change from 7% to 92% cardiomyocytes). Enriched cardiomyocytes 
expressed high levels of cardiac specific markers and displayed cardiac-specific action 
potentials, demonstrating that functionality was not compromised by drug selection. In 
another example, lipofection was used to transfect hESCs with plasmids encoding GFP 
placed under the transcriptional control of a motor neuron specific enhancer within the 5’-
regulatory region of the gene encoding the transcription factor Hb9. Motor neurons induced 
in vitro with the growth factor SHH and retinoic acid activated Hb9-driven GFP expression, 
allowing their isolation by FACS. Sorted cells achieved physiological and functional 
maturation in vitro, demonstrating the feasibility of promoter/enhancer-based FACS for the 
isolation of specific derivatives from hESCs. Chemical transfection has also been used to 
generate hESC lines with fluorescent reporter transgenes under transcriptional control of 
murine albumin (Lavon and Benvenisty, 2005; Lavon et al., 2004) and Pdx1 (Lavon et al., 
2006) genes in order to identify hESC differentiating toward the hepatic and pancreatic 
lineages, respectively. 
2.4 Lentiviral systems 
Lentiviral vectors offer another strategy to stably introduce DNA into hESCs. Pfeifer et al. 
first reported the use of lenti-viral vectors for high levels of transduction efficiency without 
transgene silencing in hESCs (Pfeifer et al., 2002). Specifically, almost 100% efficiency was 
reported at a multiplicity of infection of 50, and transgene expression was maintained over 
several passages. Several additional groups have reported high-level sustained transgene 
expression in hESCs and hESC derivatives using similar viral vectors. For example, Gropp 
et al. used lentiviral vectors to stably transduce a GFP encoding transgene under the control 
of an EF1α promoter (Gropp et al., 2003). Transduction of hESCs with these lentiviral 
vectors allowed for stable transgene expression for long-term (38 weeks) undifferentiated 
culture. Furthermore, transgene expression was not silenced upon differentiation as 
demonstrated by continuous GFP expression throughout differentiation both in vitro (EB 
formation) and in vivo (teratoma formation).  
Lentiviral vectors have also been used to identify and select hESC derivative cell 
populations. For example, Huber et al. generated stable transgenic hESC lines using 
lentiviral vectors and isolated single-cell clones that expressed a GFP transgene under the 
transcriptional control of a cardiac specific promoter, human myosin light-chain-2V 
promoter (Huber et al., 2007). As hESCs differentiated, GFP expressing cells were isolated 
and purified to near homogeneity using FACS. The GFP-positive cells stained for cardiac 
specific markers, expressed cardiac-specific genes, displayed cardiac-specific action-
potentials, and demonstrated long-term engraftment in rat hearts. A recent report expanded 
on these methods to engineer hESCs with lentiviral vectors that combined blasticidin, 
neomycin, and puromycin resistance based drug selection of pure populations of stem cells 
and cardiomyocytes with constitutive or lineage-specific promoters that control expression 
of fluorescent proteins. This allowed for cardiomyocytes and their progenitors to be 
visualized and tracked (Kita-Matsuo et al., 2009). Specifically, hESCs were infected with 
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lenti vectors carrying Brachyury (T) and α-myosin heavy chain (αMHC) promoters driving 
expression of fluorescent or drug-resistance proteins. HESCs differentiated to early 
mesoderm and cardiomyocytes were enriched using cell sorting or drug selection.  
Moreover, a drug selection differentiation protocol yielded 96% pure cardiomyocytes that 
could be cultured for over 4 months. Additionally, these drug-selected cardiomyocytes 
exhibited a gene expression profile similar to that of adult human cardiomyocytes and 
generated force and action potentials consistent with normal fetal cardiomyocytes. 
Lentiviral approaches have also been used to engineer hESCs with glial fibrillary acidic 
protein (GFAP) (Dhara et al., 2009) and alpha-fetoprotein (AFP) (Chiao et al., 2008) 
promoters driving expression of genes encoding fluorescent proteins to enrich for hESCs 
differentiating towards the neural and hepatic lineages, respectively. 
2.5 Comparison of random transgenic methods 
Very few studies have directly compared the non-viral and viral gene delivery methods 
discussed above. A recent study compared the transduction efficiencies and effect on cell 
viability of each method in several hESC lines using a fusion construct with an ubiquitin 
promoter driving GFP and firefly luciferase along with a neomyocin selection marker (Cao 
et al., 2009). Lentiviral transduction demonstrated the highest efficiency (range: 22.4-25.3%) 
with >95% cell viability. Nucleofection demonstrated significantly lower efficiency (range: 
5.8-16.1%) with moderate cell survival (range: 70-75%). Minimal transfection efficiency was 
observed with electroporation (range: 1.9-2.1%) and lipofection (range: 1.3-1.5%). 
Electroporation resulted in the lowest cell survival (range: 38-58%) while cell survival with 
lipofection (>90%) was comparable to that of lentiviral infection. Moreover, lentiviral 
transduction resulted in the greatest number of hESCs stably expressing the fusion reporter 
gene. 
Even though lentiviral transduction results in the highest efficiency and cell survival of all 
transgenic approaches, it has several drawbacks that may make use of other transgenic 
methods more attractive. One major weakness of lentiviral methods is that constructs larger 
than 6-8 kb package poorly, thereby reducing the efficiency of transduction and limiting the 
size of DNA that can be used (Kumar et al., 2001). Another disadvantage of lentiviral vectors 
is that they integrate randomly and thus have the ability to activate or inactivate nearby 
genes (Kohn et al., 2003). A final concern that may limit the use of lentiviral vectors is that 
viral transgenes may be silenced in the infected cells. Several studies have shown that gene 
silencing can occur during propagation of undifferentiated ESCs (Cherry et al., 2000) as well 
as during differentiation (Laker et al., 1998). Such silencing is likely due to epigenetic 
modifications of the viral DNA following its integration. Furthermore, studies have 
demonstrated that transgenes delivered by lentiviral vectors are suppressed in ESCs in a 
promoter-dependent manner (Hong et al., 2007; Xia et al., 2007). For example, Xia et al. 
examined the silencing of four ubiquitous promoters in lentiviral vectors driving expression 
of GFP in hESCs: CMV, hybrid CMV enhancer/chicken β-actin (CAG), phosphoglycerate 
kinase (PGK) and EF1α (Xia et al., 2007). By calculating the ratio between the percentage of 
nonfluorescent cells and the GFP copy number per cell, the authors showed that more than 
95% of the GFP copies driven by the CMV or CAG promoter and 75% of the GFP copies 
driven by the EF1α promoter were inactive. Meanwhile, GFP driven by the PGK promoter 
showed the least extent of suppression with ~55% inactive. Results such as these clearly 
demonstrate that genes delivered through the use of lentivirus are highly susceptible to 
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gene silencing and that the choice of promoter is critical for long term ubiquitous expression 
of transgenes. Whether similar gene silencing occurs with cell- and tissue-specific promoters 
remains to be explored. 
3. Site-specific recombination 
One way to avoid the problems caused by random integration of transgenes into the 
genome is the creation of hESCs lines where large, complex genetic elements can be stably 
introduced into cells at defined chromosomal locations in a single copy. Several studies have 
identified sites on chromosomes 2, 6, 10, 12, 13, 17, and 21 that are transcriptionally active in 
undifferentiated hESCs and remain transcriptionally active upon differentiation into all 
tested mature cell populations (Costa et al., 2005; Irion et al., 2007; Thyagarajan et al., 2008). 
Two strategies that have been used for site-specific recombination to introduce transgenes 
into hESCs are the Cre/loxP and phiC3I recombination systems. 
3.1 Cre/lox  
The Cre protein is a site-specific DNA recombinase that catalyzes the recombination of DNA 
between loxP sequences which contain binding sites for Cre. When cells that have loxP sites 
in their genome express Cre, a recombination event occurs between the loxP sites 
(Bouhassira et al., 1997). Depending on the orientation of the loxP sites relative to each other, 
the recombination reaction can result in an insertion, deletion (direct repeat of two loxP 
sites), inversion (two inverted loxP on the same chromosome), or translocation (two loxP 
sties on different chromosomes). Nolden et al. first reported the Cre-mediated 
recombination of a chromosomally integrated loxP-modified allele in hESCs and hESC 
derived neural progenitors (Nolden et al., 2006). In this system, a constitutively active CAG 
promoter drove transcription of the HcRed (an enhanced version of red fluorescent protein 
[RFP]) while a neomycin-resistance gene (Neo) was under transcriptional control of the PGK 
promoter, thus allowing for selection of stable clones. Cre-mediated recombination caused 
deletion of HcRed and Neo resulting in the expression of a second reporter GFP. In another 
study, Cre-mediated recombination was used to insert genes at the human homolog of the 
mouse Rosa26 locus (hROSA26) (Irion et al., 2007). Specifically, a vector containing a loxP-
flanked promoterless Neo-resistance gene followed by an inverted RFP variant, tandem 
dimer RFP (tdRFP), flanked by mutant loxP2272 was targeted to the hROSA26 locus using 
homologous recombination (see below for further discussion of homologous 
recombination). The loxP and mutant loxP2272 sites were positioned so that after Cre 
expression, the neomycin resistance cassette was deleted and the tdRFP is inverted, placing 
it under control of the endogenous hROSA26 promoter. The use of wildtype and mutant 
loxP allowed for the exchange of the tdRFP cassette with any cDNA of interst at the 
hROSA26 locus using Cre recombinase-mediated cassette exchange. 
One drawback of the Cre-loxP system is that its efficiency depends on the level of Cre 
expression, which is typically achieved by either transfection or viral methods. As a result, 
recombination only occurs in a low percentage of the cell population (10-15%). As an 
alternative strategy to introduce Cre, several groups have reported the use of cell-permeable 
versions of Cre recombinase that induce recombination by direct protein delivery and lead 
to higher levels of recombination (>90%) (Jo et al., 2001; Joshi et al., 2002; Will et al., 2002).  
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3.2 phiC3I 
Another method to carry out site-specific recombination in hESCs is the use of 
bacteriophage phiC3I integrase. Unlike Cre recombinase, the phiC3I catalyzes 
recombination between non-identical sites which makes recombination unidirectional, 
ensuring that integrated constructs do not act as substrates for the reverse excision reaction. 
PhiC3I carries out site-specific recombination between its attachment site (attB) and an 
attachment site (attP) in host DNA. Moreover, phiC3I integrases target a small number of 
loci (pseudo-attP sties) in transcriptionally active regions (“hot spots”) of the human 
genome.  
Recently, hESC lines were developed in which phiC31 integrase was used to place a target 
site for the R4 integrase into a pseudo attP site, and the R4 integrase was used to place genes 
of interest into the specific R4 target site (Figure 1) (Liu et al., 2009; Thyagarajan et al., 2008). 
Specifically, hESCs were co-transfected with a plasmid with a CMV promoter driving 
expression of phiC3I integrase and a plasmid containing the R4 attP target site upstream of a 
promoter-less Zeocin-resistance gene, as well as a hygromycin-resistance marker and a 
phiC3I attB site (pJTI/Zeo). Individual colonies carrying a R4 attP site upstream of the 
Zeocin selectable marker was achieved with selection with hygromyocin and screened for 
insertion into one of the genome’s pseudo-att sites (e.g. chromosomal location 13q32 
represents a hot spot). Retargeting these “R4” cell lines was achieved by co-transfecting a 
plasmid expressing the R4 integrase with a plasmid that had the human EF1α promoter 
upstream of the complementary R4 attB recognition site (pER4B-EG and pER4B-hOG). 
Recombination between the R4 attP and attB sites positioned the EF1α promoter upstream of  
 
 
Fig. 1. Site-specific recombination strategy using phiC3I integrase. In the first step a “platform 
line” is created using phiC3I integrase, which mediates site-specific recombination of the 
pJTI/Zeo plasmid into one of the host cell genome’s pseudo-att sites. In a second “retargeting” 
step, the R4 integrase mediates site-specific recombination of the pER4B vector with the 
previously inserted att site. Proper R4 recombination events lead to the transcriptional 
activation of the Zeocin-resistance gene. Figure and legend adapted from Liu et al., 2009. 
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the Zeocin-resistance gene. Thus, only clones that had undergone a site-specific 
recombination event were resistant to Zeocin. This method has been used to place cassettes 
with GFP driven by promoters such as EF1α and OCT4 in specific loci in hESCs. Retargeting 
was extremely efficient with an average of 17 colonies per 106 transfected cells with all 
Zeocin resistant clones containing a single integration event occurring at the chromosome 
13q23 hot spot. 
A major disadvantage of the phiC3I site-specific integration techniques is that it requires the 
generation of “platform” hESC lines (e.g. the “R4” cell line). Although retargeting efficiency 
is extremely high (100% after Zeomycin selection), initial targeting to one of the pseudo-att 
sites is inefficient and requires the screening of hundreds of clones. Given that hESC lines 
vary in their behavior and propensity to differentiate into various lineages (Osafune et al., 
2008), multiple “platform” lines would need to be generated. 
4. Homologous recombination 
Homologous recombination (HR) has long been a powerful “reverse genetics” approach to 
interrogate gene function in mice. Methods for HR exploit the endogenous DNA repair and 
recombination machinery to alter specific sequences within the genome by aligning the 
engineered transduced DNA sequences with genomic sequences. The outcome can include 
single base pair mutations, deletion of entire exons or open reading frames, and insertion of 
sequences that encode protein tags or reporter proteins, such as fluorescent proteins. In 
contrast to other genetic modifications described above, HR faithfully reproduces expression 
patterns of genes with largely insignificant effects on expression of neighboring genes. 
There are three main reasons to target genes by HR in hESCs. First, hESC lines can be 
designed to express a reporter gene under the control of an endogenous and 
developmentally regulated promoter. Such marker lines are useful to monitor and 
interrogate the developmental progression from undifferentiated to mature cell states and to 
optimize protocols for efficient and directed differentiation. By using cell isolation and 
purification methods, such as FACS, even extremely rare and specialized cell types can be 
isolated and separated from other cell types, especially from undifferentiated hESC that 
carry the potential to generate tumors. Such purified cell populations are essential for cell 
transplantation studies and eventual cell replacement therapies. Second, efficient HR can be 
used to attach tags onto genes so that the function of their protein products can be studied in 
vitro and in vivo. By modifying genes with tags that permit detection and purification, 
endogenous protein function can be explored without relying on current overexpression 
approaches that are prone to yield artifactual results. Finally, HR can be employed to 
introduce specific mutations in disease-associated genes to develop models of human 
disease. Currently, the majority of research to study human diseases in cell culture utilize 
hiPSCs derived from patients with specific genetic defects or predispositions. However, 
methods for iPSC generation are still wrought with potential complications, e.g. the various 
transgenes required for reprogramming may influence disease progression. Efficient HR in 
hPSCs would provide a powerful alternative method to insert mutations in disease 
associated genes and model human diseases.  
In comparison to murine ESCs, a limited, yet gradually expanding number of genes has 
been modified by HR in hESCs (see Table 1 for examples). One reason for the limited 
success of HR is that hPSCs, in contrast to murine ESCs, grow poorly as single cells, a 
necessary condition to isolate the cells carrying the rare HR events. This problem can be 
www.intechopen.com
Gene Transduction Approaches in Human Embryonic Stem Cells   
 
285 
partially overcome by treating dissociated cells with ROCK inhibitor, which has been shown 
to increase survival of dissociated hESCs (Damoiseaux et al., 2009; Watanabe et al., 2007). 
Most reports of HR in hESCs have targeted the X-chromosome linked HPRT1 (Hypoxanthine-
guanine phosphoribosyltransferase) locus, a gene which is inherently easier to target since 
deletion of the single copy of HPRT in male cells yields cells that are resistant to the drug 6-
Thioguinine (6-TG). While these studies provide compelling proof-of-principle, methods for 
HR in hESC are far from optimized. In this section, we discuss four methods that show great 
promise in generating HR in hESCs. 
4.1 Conventional HR method 
The conventional HR method in mESCs utilizes standard transduction methods, such as 
electroporation (see descriptions above), to introduce linearized DNA constructs comprised of 
homology arms of 3 to 5 kilo bases (kb) flanking drug selection cassettes, such as Neomycin or 
Hygromycin resistance genes. These drug resistance genes are placed between the homology 
arms to disrupt or delete one or more exons of the targeted gene. Positive drug selection alone 
yields both targeted and random insertions into the genome. To increase the frequency of 
targeted insertions, many strategies incorporate a negative selectable marker, generally Herpes 
simplex virus thymidine kinase (HSV-TK), which confers sensitivity to Gancyclovir (Ganc), 
inserted distally to one of the homology arms (Mansour et al., 1988). Cells in which a random 
insertion has occurred will have retained HSV-TK and will consequently be eliminated in the 
presence of Ganc. Cells that are resistant to Ganc have not integrated the HSV-TK gene, thus 
potentially representing a HR event. HR rates, which vary between <0.1-5%, are generally 
indicated as a percentage of cells carrying a targeted insertion (as determined by Southern blot 
or PCR) among all Neomycin resistant clones. To further increase targeting efficiencies it is 
critical to utilize isogenic DNA, i.e. the DNA used to create the homology arms in the targeting 
vector matches the DNA of the cells used for targeting. While this is possible with the various 
in-bred mouse strains, the large number of single nucleotide polymorphisms (SNP) in the 
human population (one every 1,000 base pairs) rule out an approach that utilizes isogenic 
DNA. However, it is noteworthy that two reports found that HR in humans is efficient even 
with non-isogenic DNA (Sedivy et al., 1999; Urbach et al., 2004). The need for isogenic DNA is 
overcome as the length of the homology arms increases, however, plasmids of greater than 15 
kb are difficult to engineer and propagate. This size restriction is overcome with the use of 
bacterial artificial chromosomes (see below). Due to the low targeting frequencies observed for 
many loci, this conventional HR method rarely succeeds at disrupting both copies of a gene. 
To date only a small number of genes have been successfully targeted in hESCs using positive-
negative selection methods (see Table 1).  
 
Gene hESC line HR Method Efficiency Reference 
ATM HUES9, 
H9 
BAC 21% (3/14) for first 
allele, 27% (10/37) for 
second allele 
(Song et al., 
2010) 
FEZF2 HUES9 Conventional positive 
(Neo)-negative (HSV-
TK) selection 
1.5% (2/130 clones) (Ruby and 
Zheng, 2009) 
HMGA1 BG01, 
BG02, H1 
AAV 96% (24 of 25 HygR 
clones) 
(Khan et al., 
2010) 
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H1 Conventional positive 
(Neo)-negative (6TG) 
selection 
2% (7 6-TGR out of 350 
G418R) 
(Zwaka and 
Thomson, 2003) 
H13 Conventional positive 
(Hyg)-negative (6TG) 
selection 
~1-2% (Urbach et al., 
2004) 
H1 Conventional positive 
(Neo)-negative (6TG) 
selection 
2.3% (6 6TGR out of 
260 G418R) 
(Di Domenico et 
al., 2008) 
KhES-1 HDAdV 45% (14 of 31 GancR 
and G418R clones) 
(Suzuki et al., 
2008) 
HUES3, 
HUES 8 
BAC HUES3: 1 of 3 PuroR 
clones 
HUES8: 1of 6 PuroR 
clones 
(Song et al., 
2010) 
HPRT1 
 
BG01, 
iPSCs 
AAV BG01: 26% (8 of 31 
G418R clones) 
iPSCs: 19-29% 
(Khan et al., 
2010) 
IL2RG HUES1, 
HUES3 
ZFN and IDLV 13-39% (Lombardo et 
al., 2007) 
MIXL1 HES3 Conventional positive 
(Neo) selection 
Not indicated (Davis et al., 
2008) 
OLIG2 BG01 Conventional positive 
(Neo)-negative (HSV-
TK) selection 
5.7% (6/106 clones) (Xue et al., 2009) 
p53 HUES9, 
H9 
BACs 3.3% (2/60) for first 
allele, 22% (7/32) for 
second allele 
(Song et al., 
2010) 
PIG-A H1, H9, 
iPSC lines 
ZFN 50% (6 out 12 HygR 
clones) 
(Zou et al., 2009) 
PITX3 BG01, 
iPSCs 
ZFN 11% (Hockemeyer et 
al., 2009) 
H1 Conventional positive 
(Neo) selection 
27% (28/103 G418R 
clones) 
39% (22/56 G418R 
clones) 
(Zwaka and 
Thomson, 2003) 
POU5F1 
(OCT4) 
BG01 ZFN 39-100% depending on 
ZFN pair 
(Hockemeyer et 
al., 2009) 
ROSA26 HES2 Conventional positive 
(Neo)-negative (D-TA) 
selection 
2.3% (2/88 G418R 
clones) 
(Irion et al., 
2007) 
Table 1. Examples of genes targeted by homologous recombination in hPSCs. Abbreviations: 
6-TGR = resistance to drug 6-thioguanine; BAC = Bacterial artificial chromosome; D-TA = 
diphtheria toxin A-fragment; G418R = resistance to drug G418; GancR = resistance to drug 
ganciclovir; HSV-TK = herpes simplex virus thymidine kinase; HygR = resistance to drug 
Hygromycin; IDLV = integration defective lenti virus; iPSC = induced pluripotent stem cell; 
Neo = Neomycin; PuroR = resistance to drug Puromycin; ZNF = Zinc finger nuclease. 
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4.2 BAC-based HR 
A major reason for the low HR efficiency observed for conventional methods in both mouse 
and human ESCs is related to the limited length of homology arms. It has been documented 
that with an increase in homology arm lengths from 1.3 to 6.8 kb, gene targeting frequencies 
dramatically increase (Hasty et al., 1991), and further lengthening homology regions 
increases targeted gene insertion frequencies. The upper limit for the length of conventional 
targeting vectors is approximately 20 kb, with standard targeting vectors carrying 
approximately 10 kb of homologous DNA (e.g. a short and long arm of 4 and 6 kb, 
respectively). Bacterial artificial chromosomes (BACs) with usual insert sizes of 150-350 kb 
(and up to 700 kb) provide a unique tool to overcome the length constraint of conventional 
targeting vectors. Manipulation of these large DNA constructs requires recombineering 
technologies (Copeland et al., 2001), which exploits the HR system of Escherichia coli to 
generate large recombinant DNA constructs. Importantly, the large homology regions 
overcome the need for isogenic DNA, thus permitting HR in hESCs of various genetic 
backgrounds. 
A recent report described successful BAC-based HR in hESCs at three loci, p53, ATM and 
HPRT, with targeting efficiencies of 21 to 27% (Song et al., 2010). The linearized BAC-
targeting vectors were transduced into hESCs, both HUES9 and H9, by electroporation. 
Using the same targeting vectors with an alternative drug selection cassette, the authors 
were able to generate homozygous mutants in ATM and p53. One frequently cited 
drawback of BAC-based gene targeting is the difficulty in distinguishing HR from random 
integration. Song et al. overcame this challenge by shortening one homology arm to less 
than 10 kb while retaining the other at 80 to 100 kb. This allowed confirmation of HR by 
Southern blotting and a ligation-mediated PCR. 
4.3 Zinc finger nucleases mediated HR 
It has been well documented that double-stranded DNA breaks significantly enhance HR in 
human cells (Porteus and Carroll, 2005; Porteus et al., 2003). Such double-stranded breaks 
(DSB) are then repaired either by nonhomologous end joining (NHEJ), which is highly error 
prone thereby disrupting the targeted gene, or by homology-directed repair (HDR), where 
the sequence of a homologous strand of DNA (generally the intact homologous 
chromosome) is accurately copied. However, introduction of a single DSB in the genome is 
impossible with conventional restriction enzymes.  
Zinc-finger nucleases (ZFN) offer a unique technology for cutting at single sites within the 
genome. In this approach a Zinc-finger DNA binding domain of the C2H2 class is 
engineered to recognize a single DNA sequence of interest and fused to an endo-nuclease, 
generally Fok1. Since Fok1 needs to dimerize to cleave DNA, two Zinc-finger DNA binding 
proteins with oppositely oriented binding sites are engineered. These two ZFNs are 
designed to be highly specific so that the Fok1 nuclease introduces a single DSB in the entire 
genome. One study demonstrated that design of the ZFN can greatly affect targeting 
efficiency, with rates varying between 39 to 100% for three distinct ZFN pairs designed to 
the OCT4 locus (Hockemeyer et al., 2009). In addition to the difficult and time-consuming 
nature of ZFN design and construction, it should be noted that site-specificity is difficult to 
control and off-target cleavage events have been observed (Radecke et al., 2010). As the ZFN 
introduces a single DSB, the DNA repair machinery will either introduce a deletion at the 
break site by NHEJ, or, if an exogenous DNA fragment is provided, a genetic modification 
near the DSB by HDR.  
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The ZFN technology has been successfully applied in multiple organisms, including 
Zebrafish, and in mouse and human cell culture, including hESC and hiPSCs (Davis and 
Stokoe, 2010; Hockemeyer et al., 2009; Lee et al., 2010a, b; Lombardo et al., 2007; Porteus and 
Carroll, 2005; Zou et al., 2009). A major obstacle to successfully applying this method is that 
two ZFNs and the homologous DNA have to be co-delivered into the cells of interest. 
Lombardo et al. addressed this issue by utilizing integration defective lentiviral vectors 
(IDLV) to co-deliver the ZFNs and the donor sequence. While this method yielded HR at the 
targeted site, the IL-2 receptor common γ-chain gene (IL2RG), in hESCs (Lombardo et al., 
2007), such IDLVs are potentially capable of integrating randomly into the genome, thereby 
potentially disrupting critical genes. 
An alternative virus free application of ZFNs in hESCs and hiPSCs was recently reported to 
target the PIG-A locus and a chromosomally integrated GFP gene (Zou et al., 2009). In this 
study, the donor DNA (2 kb homology arm) was transduced with or without the DNA 
encoding the ZFNs, into hESCs under optimized conditions that included the use of an 
immortalized cell line (W3R) that expresses Wnt3a, a growth factor that promotes hESC 
growth (Cai et al., 2007). The Amaxa Nucleofector® Technology was employed to achieve 
50% transfection efficiency and high stable integration rates (10-5 cells). In the presence of the 
ZFNs, HR frequencies were increased 200 to 2,000 fold. 
4.4 Adenoviral vector- and adeno associated viral-mediated HR. 
Adenoviral vectors (AdVs) have been used extensivley to transduce a broad range of cell 
types, including hPSCs, and are used in pre-clinical studies involving gene therapy. AdVs 
have been modified to remove all viral genes from the viral genome, thereby producing 
helper-dependent AdVs (HDAdVs) that are less cytotoxic than their wildtype counterparts. 
Suzuki et al. used HDAdV to successfully target the HPRT1 locus in hESCs at high efficiency 
(Suzuki et al., 2008). 
Adeno-associated virus (AAV) is a single-stranded DNA virus, which derives its name from 
the fact that it is often found in cells that are simultaneously infected with adenovirus. 
However, in contrast to adenovirus, AAV does not elicit a host immune response or 
stimulate inflammation and can infect non-dividing cells. Wildtype AAV predominately 
integrates into one location on human chromosome 19. Like adenovirus, AAV can be 
engineered to remove all viral genes, including those needed for integration, and has been 
utilized for HR in mammalian cell culture (Hirata et al., 2002; Porteus et al., 2003; Russell 
and Hirata, 1998; Vasileva and Jessberger, 2005; Vasileva et al., 2006), including hESCs and 
hiPSCs (Khan et al., 2010). 
Upon endocytosis, a wildtype AAV particle moves to the nucleus via motor proteins in the 
cytoplasm and nuclear tubular structures (Seisenberger et al., 2001), thereby “protecting” 
the single stranded genome on its journey to the nucleus. Once within the nucleus, “the 
linear single-stranded monomers mimic DNA damage and induce DNA-repair pathways” 
(Vasileva and Jessberger, 2005). In Escherichia coli it is well established that single stranded 
DNA triggers DNA repair via the SOS system. Consequently, it has been postulated that in 
eukaryotic cells, single stranded DNA would trigger a similar DNA repair process. The 
various methods described above involve donor DNA that is double stranded, which only 
efficiently triggers a DNA response pathway and homology-based repair when double 
stranded breaks exist in the genome. Thus, with its single stranded DNA genome, 
recombinant AAV may represent an ideal substrate for HR. 
www.intechopen.com
Gene Transduction Approaches in Human Embryonic Stem Cells   
 
289 
With a genome of 4.8 kb, AAV provides limited capacity of targeting vector design. At the 
same time, this limited genome size greatly simplifies cloning strategies relative to the 
coventional methods or BAC recombineering. Targeting vectors can be designed to replace 
all viral sequences except two essential palindromic inverted terminal repeats (ITR) flanking 
the donor DNA. In contrast to the conventional HR methods and BAC-mediated HR, left 
and right homology arms of 1 kilobase length have been shown to be sufficient to promote 
high HR rates using AAV. To permit selection of infected cells, the recombinant AAV can be 
constructed to contain drug selection genes under control of a constitutive promoter. HESCs 
can be efficiently infected with AAV serotype 2, 4 and 5 (Smith-Arica et al., 2003), and 
among drug selected clones HR frequencies approaching 100% have been reported (Hirata 
et al., 2002; Khan et al., 2010; Porteus et al., 2003; Suzuki et al., 2008; Vasileva et al., 2006). 
5. Concluding remarks 
Manipulation of gene expression using one or more of the various transgenesis methods 
described here are critical in advancing hPSC science and accelerating applications of hPSC 
in regenerative medicine. While many methods of transgenesis developed in other cell 
culture systems are available, it is clear that hPSCs exhibit unique properties and 
charcateristics so that all methods require significant refinement and optimization. The 
current differences in gene transduction efficiencies among the various hPSC lines will 
likely evaporate as culture conditions for hPSC improve and become standardized. Recent 
advances and improvements in culture substrates and media formulations specifically 
designed for hPSCs will greatly augment and enhance the current methods to modify the 
genome of hPSCs. Additionally, further development of technologies for single cell isolation 
and purification, such as flow cytometry and cell sorting, will yield transduced and targeted 
cell populations in sufficiently large numbers to permit further analysis of transgenic cell 
lines and to enable transplantation studies. 
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